A new COVID-19 vaccine developed by researchers at the CNB-CSIC appears to protect against infection of the brain and neurological symptoms associated with coronavirus.
Results of a phase three clinical trial of a novel brain cancer vaccine, DCVax-L, that uses a patient's stem cells to target cancer cells extend survival by many months to years for glioblastoma patients.
A newly developed vaccine blocks the ability of the opioid Fentanyl's ability to enter the brain, thus blocking the drug's "high".
Older adults who received at least one flu vaccination were 40% less likely to develop Alzheimer's disease over the course of a four year follow up than their peers who did not receive a vaccine.
Multiple sclerosis patients who take Rituximab have a better response to the COVID-19 vaccine if they have a higher B cell count.
Vaccine hesitance waned over time, and the majority of caregivers and dependents with ASD received the COVID-19 vaccine following FDA approval. However, overall vaccine hesitancy influenced COVID-19 vaccine uptake in a minority of caregivers and dependents with ASD. Recent findings reveal that those on the autism spectrum are at greater risk of hospitalization following COVID-19 infection, and historically, a significant portion of parents of children with ASD are more likely to delay or decline any childhood vaccines.
A new protein-based vaccine shows promise for improving bone quality and preventing rheumatoid arthritis.
Researchers report a cleaner living environment may not detrimentally impact a child's developing immune system, as current theories suggest.
Narratives and storytelling can help counter vaccine misinformation as the method can create a bridge between scientific evidence and human experience.
A number of videos have surfaced on popular channels showing people experiencing some adverse effects following the coronavirus vaccine. Researchers say some of the cases could be related to functional neurological disorder, a common neuropsychological condition.